Skip to main content

  • FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

    FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

  • FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

    On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the same active moiety, tafamidis, but they are not substitutable on a milligram to milligram basis and their recommended doses differ.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details